Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365218 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04365218 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 12 participants.
The verdict
NCT04365218, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This Phase I First in Human (FIH) study is being conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity profile of MEDI8367 across the dose range.
Interventions
- DRUG Placebo
- DRUG MEDI8367
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2021-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365218
The ClinicalTrials.gov registry entry for NCT04365218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04365218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365218 about?
NCT04365218 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease". This Phase I First in Human (FIH) study is being conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity profile of MEDI8367 across the dose range.
What is the current status of trial NCT04365218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-07-22. Estimated completion is 2021-01-03.
What interventions are being tested in trial NCT04365218?
The interventions under investigation include: Placebo (DRUG), MEDI8367 (DRUG).
Who is sponsoring clinical trial NCT04365218?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.